



Ferring Pharmaceuticals

Ferring today

- Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology.
- In recent years Ferring has expanded beyond its traditional European base and now has more than 4'000 employees and offices in 50 countries.
- Ferring's international operations are run from Saint-Prex in Switzerland and development activities are coordinated from Copenhagen, Denmark and Parsippany, USA.
- Ferring has production facilities in several European countries, Israel, China, Mexico and Argentina.
- Ferring's research and development programme supports and augments its existing treatments and will add a new generation of products to some of the company's most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China.
- Ferring is a private company owned by the Dr Frederik Paulsen Foundation.

Ferring's history

- Dr Frederik Paulsen founded the company as Nordiska Hormon Laboratoriet in two rented rooms in Malmö, Sweden in 1950.
- Ferring became a pioneer in developing and selling pharmaceutical products based upon natural, pituitary-produced peptide hormones.
- In 1961 Ferring became the first pharmaceutical company to produce synthetic peptide hormones on an industrial scale.
- In 1972 it launched MINIRIN (desmopressin), a synthetic analogue of the antidiuretic hormone vasopressin used to treat central diabetes insipidus and nocturnal enuresis, or bedwetting.
- In 1986 it launched PENTASA (mesalazine) for the treatment of mild to moderate ulcerative colitis and Crohn's disease, diseases of the gastrointestinal tract.
- In 2000 Ferring launched TRACTOCILE (atosiban), an entirely new peptide developed by the company's researchers for the treatment of pre-term labour.



- In 2002 the Ferring International PharmaScience Centre opened in Copenhagen.
- In 2002 the company launched MENOPUR (menotropin) an infertility treatment, providing a strong foundation for further progress in Assisted Reproductive Technology (ART).
- In 2005 Ferring bought Israel-based Bio-Technology General, the company's most significant acquisition.
- In 2006 Ferring opened a new headquarters and production site in Saint-Prex, Switzerland.
- In December 2008, Ferring received FDA approval for degarelix, its GnRH receptor blocker for advanced prostate cancer. Authorization in the European Union, under the brand name FIRMAGON, followed in February 2009 and the product was first launched in the US in early March 2009.

For more information, please visit: www.ferring.com